Cryo-Save logo CryoSave

overview

News & Events

global
August 29, 2016

ESPERITE N.V. (ESP) announces additional information on envisaged financing

 

Esperite N.V. (Euronext: ESP, “Esperite” or “the Group”) announced in its press release of 23 August 2016 that it prepares for a significant external funding before year end to which the main shareholder will contribute along with potential other investors.

 

Zutphen, The Netherlands – 29 August 2016

 

Esperite announces that the future financing is expected to consist of an equity raising and issuance of convertible bonds by means of a private placement.

 

The number of new shares to be issued will not exceed 20% of the currently issued share capital and hence be within the authority that has been granted by the shareholders to the board of directors during the annual general meeting of shareholders of 9 June 2016.

 

The convertible bonds would be following the same principles previously used by the company.
Esperite N.V. (Euronext: ESP, “Esperite” or “the Group”) announced in its press release of 23 August 2016 that it prepares for a significant external funding before year end to which the main shareholder will contribute along with potential other investors.


Esperite announces that the future financing is expected to consist of an equity raising and issuance of convertible bonds by means of a private placement.


The number of new shares to be issued will not exceed 20% of the currently issued share capital and hence be within the authority that has been granted by the shareholders to the board of directors during the annual general meeting of shareholders of 9 June 2016.

 

The convertible bonds would be following the same principles previously used by the company.

 

About ESPERITE

 

ESPERITE Group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and predictive medicine established in 2000.

 

To learn more about the ESPERITE group, or to book an interview with CEO Frederic Amar: +31 575 548 998 – ir@esperite.com or visit the websites at www.esperite.com and www.genoma.com.